Urinary Albumin-to-Creatinine Ratio (uACR) Point-of-Care (POC) Device with Seamless Data Transmission for Monitoring the Progression of Chronic Kidney Disease
Biosensors · 24.02.2025 · 15 (3) · 145
DOI: 10.3390/bios15030145 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biosensors, online erschienen am 24.02.2025. Verfasst von Artitaya Thiengsusuk und 8 weiteren Autor:innen. Beteiligte Einrichtung: Drug Discovery and Development Center, Office of Advanced Science and Technology, Thammasat University, Pathum Thani 12120, Thailand. Hauptthemen laut MEDLINE: Creatinine, Renal Insufficiency, Chronic, Albuminuria, Point-of-Care Systems. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NRCT, Thailand Science Research and Innovation Fundamental Fund Fiscal Year 2024, National Research Council of Thailand (NRCT).
Abstract (Originalsprache)
Chronic kidney disease (CKD) continues to pose a critical global health challenge, making ongoing monitoring vital for effective management and preventing its progression to end-stage renal disease. The urinary albumin-to-creatinine ratio (uACR) stands out as a reliable biomarker. MyACR was developed and validated as a novel point-of-care (POC) device for identifying and monitoring the progress of CKD. MyACR device operates using a colorimetric-based spectroscopy to quantify albumin and creatinine levels at 625 nm and 515 nm, respectively. Calculated uACR values were compared with results from the reference turbidimetry method using a dataset of 103 random urine samples from patients at high risk of advanced CKD. The device showed excellent performance in detecting severe nephropathy, with sensitivity, specificity, and accuracy of 100%, 100%, and 100%, respectively. The PPV (positive predictive value) was 100%, indicating perfect identification of patients with severe nephropathy (uACR > 300 mg/g creatinine). The NPV (negative predictive value) was 100%, suggesting a strong ability to rule out severe nephropathy, though a small risk of false negatives remained. Bland–Altman analysis confirmed a high level of agreement, with 96.11% (for all data) and 95.87% (for uACR > 300 mg/g creatinine) of MyACR measurements falling within the 95% confidence interval (−27 to +19). Correlation analysis revealed a significant alignment between MyACR and the reference method (r2 0.9720 to 0.9836). The ROC analysis suggested that combining uACR with the estimated glomerular filtration rate (eGFR) demonstrated strong predictive performance, yielding an area under the curve (AUC) of 0.933 (95% CI: 0.86–1.0). In conclusion, the MyACR device is a robust, affordable, and user-friendly tool for detecting nephropathy, showing performance comparable to the reference method. Its portability and cost-effectiveness make it particularly suitable for use in low-resource environments. Additionally, integrating uACR with eGFR enhances prognostic capabilities, offering a comprehensive approach to assessing kidney function and predicting CKD progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Drug Discovery and Development Center, Office of Advanced Science and Technology, Thammasat University, Pathum Thani 12120, Thailand.
- Graduate Program in Bioclinical Sciences, Chulabhorn International College of Medicine, Thammasat University, Pathum Thani 12120, Thailand.
- Department of Medical Technology Laboratory, Thammasat University Hospital, Pathum Thani 12120, Thailand.
- Department of Biomedicine and Health Informatics, Faculty of Pharmacy, Silpakorn University, Nakhon Pathom 73000, Thailand.
- Bangkok High Lab Co., Ltd., Bang Khen District, Bangkok 10220, Thailand.
- Center of Excellence in Pharmacology and Molecular Biology of Malaria and Cholangiocarcinoma, Chulabhorn International College of Medicine, Thammasat University, Pathum Thani 12120, Thailand.
ORCID-Profile: Artitaya Thiengsusuk, Runtikan Pochairach
Förderung
- NRCT
- Thailand Science Research and Innovation Fundamental Fund Fiscal Year 2024
- National Research Council of Thailand (NRCT)
- Research Fund of Chulabhorn International College of Medicine
Zitieren
APA
Thiengsusuk, A., Youngvises, N., Pochairach, R., Taha, R. O., Sirisabhabhorn, K., Muhamad, N., Meesiri, W., Chaijaroenkul, W., & Na-Bangchang, K. (2025). Urinary Albumin-to-Creatinine Ratio (uACR) Point-of-Care (POC) Device with Seamless Data Transmission for Monitoring the Progression of Chronic Kidney Disease. Biosensors, 15(3), 145. https://doi.org/10.3390/bios15030145
Vancouver
Thiengsusuk A, Youngvises N, Pochairach R, Taha RO, Sirisabhabhorn K, Muhamad N, et al. Urinary Albumin-to-Creatinine Ratio (uACR) Point-of-Care (POC) Device with Seamless Data Transmission for Monitoring the Progression of Chronic Kidney Disease. Biosensors. 2025;15(3):145. doi:10.3390/bios15030145
BibTeX
@article{Thiengsusuk2025,
author = {Thiengsusuk, Artitaya and Youngvises, Napaporn and Pochairach, Runtikan and Taha, Rehab Osman and Sirisabhabhorn, Kridsada and Muhamad, Nadda and Meesiri, Wanchai and Chaijaroenkul, Wanna and Na-Bangchang, Kesara},
title = {Urinary Albumin-to-Creatinine Ratio (uACR) Point-of-Care (POC) Device with Seamless Data Transmission for Monitoring the Progression of Chronic Kidney Disease},
journal = {Biosensors},
year = {2025},
volume = {15},
number = {3},
pages = {145},
doi = {10.3390/bios15030145}
}
EUVIMED